nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Dactinomycin—muscle cancer	0.0529	0.34	CbGbCtD
Carfilzomib—ABCB1—Vincristine—muscle cancer	0.0326	0.21	CbGbCtD
Carfilzomib—ABCB1—Etoposide—muscle cancer	0.0298	0.192	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—muscle cancer	0.0203	0.131	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—muscle cancer	0.0197	0.127	CbGbCtD
Carfilzomib—Peripheral motor neuropathy—Vincristine—muscle cancer	0.0182	0.07	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Vincristine—muscle cancer	0.012	0.0461	CcSEcCtD
Carfilzomib—Multi-organ failure—Dactinomycin—muscle cancer	0.0114	0.0439	CcSEcCtD
Carfilzomib—PSMB10—head—muscle cancer	0.0103	0.0477	CbGeAlD
Carfilzomib—Multi-organ failure—Vincristine—muscle cancer	0.0102	0.0392	CcSEcCtD
Carfilzomib—PSMB1—embryo—muscle cancer	0.0101	0.0469	CbGeAlD
Carfilzomib—PSMB10—testis—muscle cancer	0.00997	0.0461	CbGeAlD
Carfilzomib—PSMB2—embryo—muscle cancer	0.00989	0.0457	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—muscle cancer	0.00912	0.0422	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—muscle cancer	0.00797	0.0369	CbGeAlD
Carfilzomib—PSMB5—cardiac atrium—muscle cancer	0.00786	0.0364	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vincristine—muscle cancer	0.00778	0.474	CbGdCrCtD
Carfilzomib—PSMB2—smooth muscle tissue—muscle cancer	0.00778	0.036	CbGeAlD
Carfilzomib—PSMB8—tendon—muscle cancer	0.00776	0.0359	CbGeAlD
Carfilzomib—PSMB1—renal system—muscle cancer	0.00767	0.0355	CbGeAlD
Carfilzomib—Peripheral motor neuropathy—Doxorubicin—muscle cancer	0.00765	0.0294	CcSEcCtD
Carfilzomib—PSMB8—bone marrow—muscle cancer	0.00751	0.0347	CbGeAlD
Carfilzomib—PSMB2—renal system—muscle cancer	0.00748	0.0346	CbGeAlD
Carfilzomib—PSMB8—vagina—muscle cancer	0.0072	0.0333	CbGeAlD
Carfilzomib—PSMB1—cardiac atrium—muscle cancer	0.00687	0.0318	CbGeAlD
Carfilzomib—PSMB5—tendon—muscle cancer	0.00685	0.0317	CbGeAlD
Carfilzomib—PSMB2—cardiac atrium—muscle cancer	0.0067	0.031	CbGeAlD
Carfilzomib—PSMB5—bone marrow—muscle cancer	0.00664	0.0307	CbGeAlD
Carfilzomib—PSMB8—testis—muscle cancer	0.00642	0.0297	CbGeAlD
Carfilzomib—PSMB5—vagina—muscle cancer	0.00636	0.0294	CbGeAlD
Carfilzomib—PSMB1—tendon—muscle cancer	0.00599	0.0277	CbGeAlD
Carfilzomib—PSMB2—tendon—muscle cancer	0.00584	0.027	CbGeAlD
Carfilzomib—Tumour lysis syndrome—Methotrexate—muscle cancer	0.00581	0.0223	CcSEcCtD
Carfilzomib—PSMB1—bone marrow—muscle cancer	0.0058	0.0268	CbGeAlD
Carfilzomib—PSMB5—testis—muscle cancer	0.00567	0.0262	CbGeAlD
Carfilzomib—PSMB2—bone marrow—muscle cancer	0.00566	0.0262	CbGeAlD
Carfilzomib—PSMB1—vagina—muscle cancer	0.00556	0.0257	CbGeAlD
Carfilzomib—PSMB2—vagina—muscle cancer	0.00542	0.0251	CbGeAlD
Carfilzomib—PSMB1—head—muscle cancer	0.00513	0.0237	CbGeAlD
Carfilzomib—Tumour lysis syndrome—Doxorubicin—muscle cancer	0.00503	0.0193	CcSEcCtD
Carfilzomib—PSMB2—head—muscle cancer	0.00501	0.0232	CbGeAlD
Carfilzomib—PSMB1—testis—muscle cancer	0.00496	0.0229	CbGeAlD
Carfilzomib—Peripheral sensory neuropathy—Doxorubicin—muscle cancer	0.00489	0.0188	CcSEcCtD
Carfilzomib—PSMB2—testis—muscle cancer	0.00484	0.0224	CbGeAlD
Carfilzomib—Neuritis—Vincristine—muscle cancer	0.00445	0.0171	CcSEcCtD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—muscle cancer	0.00431	0.263	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—muscle cancer	0.00431	0.263	CbGdCrCtD
Carfilzomib—Multi-organ failure—Doxorubicin—muscle cancer	0.00429	0.0165	CcSEcCtD
Carfilzomib—Musculoskeletal chest pain—Doxorubicin—muscle cancer	0.0036	0.0139	CcSEcCtD
Carfilzomib—Bacterial infection—Methotrexate—muscle cancer	0.00349	0.0134	CcSEcCtD
Carfilzomib—Sepsis—Dactinomycin—muscle cancer	0.00323	0.0124	CcSEcCtD
Carfilzomib—Hepatic failure—Dactinomycin—muscle cancer	0.00301	0.0116	CcSEcCtD
Carfilzomib—Lymphopenia—Doxorubicin—muscle cancer	0.00273	0.0105	CcSEcCtD
Carfilzomib—Hepatic failure—Vincristine—muscle cancer	0.00269	0.0103	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00243	0.00935	CcSEcCtD
Carfilzomib—Hyponatraemia—Vincristine—muscle cancer	0.00242	0.00932	CcSEcCtD
Carfilzomib—Pain in extremity—Vincristine—muscle cancer	0.00241	0.00928	CcSEcCtD
Carfilzomib—Hypophosphataemia—Doxorubicin—muscle cancer	0.0024	0.00924	CcSEcCtD
Carfilzomib—Sepsis—Etoposide—muscle cancer	0.00234	0.00899	CcSEcCtD
Carfilzomib—Cardiac arrest—Vincristine—muscle cancer	0.0023	0.00882	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Doxorubicin—muscle cancer	0.0022	0.00845	CcSEcCtD
Carfilzomib—Neutropenia—Dactinomycin—muscle cancer	0.00218	0.00839	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00217	0.00836	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Etoposide—muscle cancer	0.00216	0.00829	CcSEcCtD
Carfilzomib—Pneumonia—Dactinomycin—muscle cancer	0.00209	0.00805	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—muscle cancer	0.00201	0.00773	CcSEcCtD
Carfilzomib—Neutropenia—Vincristine—muscle cancer	0.00195	0.0075	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—muscle cancer	0.00187	0.00719	CcSEcCtD
Carfilzomib—Pneumonia—Vincristine—muscle cancer	0.00187	0.00719	CcSEcCtD
Carfilzomib—Cardiac arrest—Etoposide—muscle cancer	0.00186	0.00715	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Vincristine—muscle cancer	0.00183	0.00705	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vincristine—muscle cancer	0.00182	0.00701	CcSEcCtD
Carfilzomib—Chills—Dactinomycin—muscle cancer	0.00168	0.00645	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vincristine—muscle cancer	0.00166	0.00639	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—muscle cancer	0.00158	0.00608	CcSEcCtD
Carfilzomib—Cardiac disorder—Vincristine—muscle cancer	0.00155	0.00596	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—muscle cancer	0.00152	0.00583	CcSEcCtD
Carfilzomib—ABCB1—embryo—muscle cancer	0.00151	0.00699	CbGeAlD
Carfilzomib—Anaemia—Dactinomycin—muscle cancer	0.0015	0.00578	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—muscle cancer	0.00149	0.00571	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—muscle cancer	0.00148	0.00569	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—muscle cancer	0.00148	0.00568	CcSEcCtD
Carfilzomib—Leukopenia—Dactinomycin—muscle cancer	0.00146	0.0056	CcSEcCtD
Carfilzomib—Back pain—Vincristine—muscle cancer	0.00141	0.00541	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—muscle cancer	0.0014	0.00538	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—muscle cancer	0.00135	0.00517	CcSEcCtD
Carfilzomib—Anaemia—Vincristine—muscle cancer	0.00134	0.00517	CcSEcCtD
Carfilzomib—Infection—Dactinomycin—muscle cancer	0.00132	0.00507	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—muscle cancer	0.0013	0.00501	CcSEcCtD
Carfilzomib—Leukopenia—Vincristine—muscle cancer	0.0013	0.005	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—muscle cancer	0.0013	0.005	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—muscle cancer	0.00127	0.00488	CcSEcCtD
Carfilzomib—Anorexia—Dactinomycin—muscle cancer	0.00127	0.00487	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—muscle cancer	0.00126	0.00483	CcSEcCtD
Carfilzomib—Hypertension—Vincristine—muscle cancer	0.00126	0.00482	CcSEcCtD
Carfilzomib—Chills—Etoposide—muscle cancer	0.00121	0.00467	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—muscle cancer	0.00121	0.00466	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00121	0.00465	CcSEcCtD
Carfilzomib—Infection—Vincristine—muscle cancer	0.00118	0.00453	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vincristine—muscle cancer	0.00116	0.00447	CcSEcCtD
Carfilzomib—Decreased appetite—Dactinomycin—muscle cancer	0.00115	0.00444	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—muscle cancer	0.00114	0.0044	CcSEcCtD
Carfilzomib—ABCB1—renal system—muscle cancer	0.00114	0.00529	CbGeAlD
Carfilzomib—Back pain—Etoposide—muscle cancer	0.00114	0.00438	CcSEcCtD
Carfilzomib—Pain—Dactinomycin—muscle cancer	0.00114	0.00437	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—muscle cancer	0.00113	0.00435	CcSEcCtD
Carfilzomib—Anorexia—Vincristine—muscle cancer	0.00113	0.00435	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—muscle cancer	0.00113	0.00434	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—muscle cancer	0.00112	0.0043	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—muscle cancer	0.0011	0.00422	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—muscle cancer	0.00109	0.00418	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00108	0.00416	CcSEcCtD
Carfilzomib—Insomnia—Vincristine—muscle cancer	0.00107	0.00413	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—muscle cancer	0.00105	0.00405	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—muscle cancer	0.00105	0.00404	CcSEcCtD
Carfilzomib—Decreased appetite—Vincristine—muscle cancer	0.00103	0.00396	CcSEcCtD
Carfilzomib—Cough—Etoposide—muscle cancer	0.00103	0.00395	CcSEcCtD
Carfilzomib—Fatigue—Vincristine—muscle cancer	0.00102	0.00393	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—muscle cancer	0.00102	0.00391	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—muscle cancer	0.00102	0.00391	CcSEcCtD
Carfilzomib—Pain—Vincristine—muscle cancer	0.00101	0.0039	CcSEcCtD
Carfilzomib—Constipation—Vincristine—muscle cancer	0.00101	0.0039	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—muscle cancer	0.00101	0.0039	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—muscle cancer	0.000964	0.00371	CcSEcCtD
Carfilzomib—Infection—Etoposide—muscle cancer	0.000955	0.00367	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—muscle cancer	0.000953	0.00366	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—muscle cancer	0.00095	0.00365	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—muscle cancer	0.000947	0.00364	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—muscle cancer	0.000941	0.00362	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000941	0.00362	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—muscle cancer	0.000938	0.00361	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—muscle cancer	0.000923	0.00355	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—muscle cancer	0.000916	0.00352	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000913	0.00351	CcSEcCtD
Carfilzomib—Diarrhoea—Dactinomycin—muscle cancer	0.000909	0.00349	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—muscle cancer	0.000908	0.00349	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—muscle cancer	0.000887	0.00341	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—muscle cancer	0.000865	0.004	CbGeAlD
Carfilzomib—Dyspnoea—Etoposide—muscle cancer	0.000857	0.00329	CcSEcCtD
Carfilzomib—Asthenia—Vincristine—muscle cancer	0.000851	0.00327	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—muscle cancer	0.000844	0.00325	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—muscle cancer	0.000835	0.00321	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—muscle cancer	0.000829	0.00319	CcSEcCtD
Carfilzomib—ABCB1—vagina—muscle cancer	0.000828	0.00383	CbGeAlD
Carfilzomib—Constipation—Etoposide—muscle cancer	0.000822	0.00316	CcSEcCtD
Carfilzomib—Pain—Etoposide—muscle cancer	0.000822	0.00316	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—muscle cancer	0.00082	0.00315	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000815	0.00313	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—muscle cancer	0.000812	0.00312	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—muscle cancer	0.000791	0.00304	CcSEcCtD
Carfilzomib—Nausea—Dactinomycin—muscle cancer	0.000789	0.00303	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—muscle cancer	0.000786	0.00302	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—muscle cancer	0.000785	0.00302	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—muscle cancer	0.000768	0.00295	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000766	0.00295	CcSEcCtD
Carfilzomib—ABCB1—head—muscle cancer	0.000765	0.00354	CbGeAlD
Carfilzomib—Body temperature increased—Etoposide—muscle cancer	0.00076	0.00292	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—muscle cancer	0.000754	0.0029	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—muscle cancer	0.000752	0.00289	CcSEcCtD
Carfilzomib—Headache—Vincristine—muscle cancer	0.000743	0.00286	CcSEcCtD
Carfilzomib—ABCB1—testis—muscle cancer	0.000739	0.00342	CbGeAlD
Carfilzomib—Chills—Methotrexate—muscle cancer	0.000727	0.00279	CcSEcCtD
Carfilzomib—Nausea—Vincristine—muscle cancer	0.000705	0.00271	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—muscle cancer	0.000698	0.00268	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—muscle cancer	0.000691	0.00266	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—muscle cancer	0.00069	0.00265	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—muscle cancer	0.000682	0.00262	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—muscle cancer	0.000658	0.00253	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—muscle cancer	0.000652	0.00251	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—muscle cancer	0.000651	0.0025	CcSEcCtD
Carfilzomib—PSMB2—B Cell Activation—KIT—muscle cancer	0.000636	0.00181	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—KIT—muscle cancer	0.000636	0.00181	CbGpPWpGaD
Carfilzomib—Dizziness—Etoposide—muscle cancer	0.000636	0.00244	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—muscle cancer	0.000631	0.00243	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—muscle cancer	0.00063	0.00242	CcSEcCtD
Carfilzomib—PSMB8—B Cell Activation—KIT—muscle cancer	0.000627	0.00178	CbGpPWpGaD
Carfilzomib—Cough—Methotrexate—muscle cancer	0.000615	0.00237	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—muscle cancer	0.000611	0.00235	CcSEcCtD
Carfilzomib—Headache—Etoposide—muscle cancer	0.000602	0.00231	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—FOXO4—muscle cancer	0.000601	0.00171	CbGpPWpGaD
Carfilzomib—Arthralgia—Methotrexate—muscle cancer	0.0006	0.00231	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—FOXO4—muscle cancer	0.000598	0.0017	CbGpPWpGaD
Carfilzomib—Back pain—Doxorubicin—muscle cancer	0.000591	0.00227	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—muscle cancer	0.000587	0.00226	CcSEcCtD
Carfilzomib—Infection—Methotrexate—muscle cancer	0.000572	0.0022	CcSEcCtD
Carfilzomib—Nausea—Etoposide—muscle cancer	0.000571	0.00219	CcSEcCtD
Carfilzomib—PSMB10—Cell Cycle Checkpoints—TP53—muscle cancer	0.000571	0.00162	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle Checkpoints—TP53—muscle cancer	0.000568	0.00161	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000567	0.00161	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000567	0.00161	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000567	0.00161	CbGpPWpGaD
Carfilzomib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000565	0.00161	CbGpPWpGaD
Carfilzomib—Anaemia—Doxorubicin—muscle cancer	0.000564	0.00217	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—muscle cancer	0.000564	0.00217	CcSEcCtD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000559	0.00159	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000556	0.00158	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000556	0.00158	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000556	0.00158	CbGpPWpGaD
Carfilzomib—Anorexia—Methotrexate—muscle cancer	0.000549	0.00211	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—BUB1B—muscle cancer	0.000549	0.00156	CbGpPWpGaD
Carfilzomib—Leukopenia—Doxorubicin—muscle cancer	0.000547	0.0021	CcSEcCtD
Carfilzomib—PSMB10—Immune System—CD34—muscle cancer	0.000537	0.00152	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD34—muscle cancer	0.000534	0.00152	CbGpPWpGaD
Carfilzomib—Cough—Doxorubicin—muscle cancer	0.000533	0.00205	CcSEcCtD
Carfilzomib—PSMB2—Signaling Pathways—KIDINS220—muscle cancer	0.000528	0.0015	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIDINS220—muscle cancer	0.000528	0.0015	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIDINS220—muscle cancer	0.000528	0.0015	CbGpPWpGaD
Carfilzomib—Hypertension—Doxorubicin—muscle cancer	0.000527	0.00203	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000524	0.00202	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—muscle cancer	0.000521	0.002	CcSEcCtD
Carfilzomib—PSMB8—Signaling Pathways—KIDINS220—muscle cancer	0.000521	0.00148	CbGpPWpGaD
Carfilzomib—Arthralgia—Doxorubicin—muscle cancer	0.00052	0.002	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—muscle cancer	0.000513	0.00197	CcSEcCtD
Carfilzomib—PSMB1—Metabolism—FH—muscle cancer	0.000509	0.00145	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—FH—muscle cancer	0.000509	0.00145	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—FH—muscle cancer	0.000509	0.00145	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—FH—muscle cancer	0.000502	0.00143	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—MDM2—muscle cancer	0.000501	0.00142	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—MDM2—muscle cancer	0.000501	0.00142	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—MDM2—muscle cancer	0.000501	0.00142	CbGpPWpGaD
Carfilzomib—Decreased appetite—Methotrexate—muscle cancer	0.0005	0.00192	CcSEcCtD
Carfilzomib—PSMB5—Cell Cycle—BUB1B—muscle cancer	0.000497	0.00141	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—BUB1B—muscle cancer	0.000497	0.00141	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—BUB1B—muscle cancer	0.000497	0.00141	CbGpPWpGaD
Carfilzomib—Fatigue—Methotrexate—muscle cancer	0.000496	0.00191	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—muscle cancer	0.000495	0.0019	CcSEcCtD
Carfilzomib—PSMB8—B Cell Activation—MDM2—muscle cancer	0.000494	0.0014	CbGpPWpGaD
Carfilzomib—Pain—Methotrexate—muscle cancer	0.000492	0.00189	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle—BUB1B—muscle cancer	0.00049	0.00139	CbGpPWpGaD
Carfilzomib—Thrombocytopenia—Doxorubicin—muscle cancer	0.000488	0.00188	CcSEcCtD
Carfilzomib—PSMB10—Gene Expression—MED12—muscle cancer	0.000488	0.00139	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MED12—muscle cancer	0.000486	0.00138	CbGpPWpGaD
Carfilzomib—Anorexia—Doxorubicin—muscle cancer	0.000475	0.00183	CcSEcCtD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000462	0.00131	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—TP53—muscle cancer	0.000456	0.00129	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—FOXO4—muscle cancer	0.000456	0.00129	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—FOXO4—muscle cancer	0.000456	0.00129	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—FOXO4—muscle cancer	0.000456	0.00129	CbGpPWpGaD
Carfilzomib—Body temperature increased—Methotrexate—muscle cancer	0.000455	0.00175	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000454	0.00175	CcSEcCtD
Carfilzomib—PSMB9—Apoptosis—TP53—muscle cancer	0.000454	0.00129	CbGpPWpGaD
Carfilzomib—Insomnia—Doxorubicin—muscle cancer	0.000451	0.00173	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—FOXO4—muscle cancer	0.000449	0.00128	CbGpPWpGaD
Carfilzomib—Dyspnoea—Doxorubicin—muscle cancer	0.000444	0.00171	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—FOXO1—muscle cancer	0.000444	0.00126	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—FOXO1—muscle cancer	0.000442	0.00126	CbGpPWpGaD
Carfilzomib—Decreased appetite—Doxorubicin—muscle cancer	0.000433	0.00167	CcSEcCtD
Carfilzomib—PSMB1—Cell Cycle Checkpoints—TP53—muscle cancer	0.000433	0.00123	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle Checkpoints—TP53—muscle cancer	0.000433	0.00123	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle Checkpoints—TP53—muscle cancer	0.000433	0.00123	CbGpPWpGaD
Carfilzomib—Fatigue—Doxorubicin—muscle cancer	0.00043	0.00165	CcSEcCtD
Carfilzomib—PSMB8—Cell Cycle Checkpoints—TP53—muscle cancer	0.000426	0.00121	CbGpPWpGaD
Carfilzomib—Constipation—Doxorubicin—muscle cancer	0.000426	0.00164	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—muscle cancer	0.000426	0.00164	CcSEcCtD
Carfilzomib—PSMB10—Disease—ENO2—muscle cancer	0.000413	0.00117	CbGpPWpGaD
Carfilzomib—Asthenia—Methotrexate—muscle cancer	0.000413	0.00159	CcSEcCtD
Carfilzomib—PSMB9—Disease—ENO2—muscle cancer	0.000411	0.00117	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD34—muscle cancer	0.000407	0.00116	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD34—muscle cancer	0.000407	0.00116	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD34—muscle cancer	0.000407	0.00116	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD34—muscle cancer	0.000401	0.00114	CbGpPWpGaD
Carfilzomib—Body temperature increased—Doxorubicin—muscle cancer	0.000394	0.00151	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—muscle cancer	0.000394	0.00151	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—muscle cancer	0.000381	0.00146	CcSEcCtD
Carfilzomib—PSMB10—Metabolism—MED12—muscle cancer	0.000379	0.00108	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—MED12—muscle cancer	0.000378	0.00107	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HMGA1—muscle cancer	0.000375	0.00107	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HMGA1—muscle cancer	0.000374	0.00106	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MED12—muscle cancer	0.00037	0.00105	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MED12—muscle cancer	0.00037	0.00105	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MED12—muscle cancer	0.00037	0.00105	CbGpPWpGaD
Carfilzomib—Vomiting—Methotrexate—muscle cancer	0.000366	0.00141	CcSEcCtD
Carfilzomib—PSMB10—Immune System—FOXO4—muscle cancer	0.000365	0.00104	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MED12—muscle cancer	0.000365	0.00104	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—FOXO4—muscle cancer	0.000363	0.00103	CbGpPWpGaD
Carfilzomib—Headache—Methotrexate—muscle cancer	0.000361	0.00139	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—muscle cancer	0.000358	0.00137	CcSEcCtD
Carfilzomib—PSMB10—Metabolism—ENO2—muscle cancer	0.000346	0.000983	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TP53—muscle cancer	0.000345	0.000981	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TP53—muscle cancer	0.000345	0.000981	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—TP53—muscle cancer	0.000345	0.000981	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ENO2—muscle cancer	0.000344	0.000978	CbGpPWpGaD
Carfilzomib—Nausea—Methotrexate—muscle cancer	0.000342	0.00131	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—muscle cancer	0.000341	0.00131	CcSEcCtD
Carfilzomib—PSMB8—Apoptosis—TP53—muscle cancer	0.000341	0.000967	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KIT—muscle cancer	0.000338	0.000961	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000338	0.000961	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—KIT—muscle cancer	0.000337	0.000957	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—FOXO4—muscle cancer	0.000337	0.000957	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—FOXO1—muscle cancer	0.000337	0.000956	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—FOXO1—muscle cancer	0.000337	0.000956	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—FOXO1—muscle cancer	0.000337	0.000956	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000335	0.000953	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—FOXO4—muscle cancer	0.000335	0.000952	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000334	0.000948	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—FOXO1—muscle cancer	0.000332	0.000943	CbGpPWpGaD
Carfilzomib—Dizziness—Doxorubicin—muscle cancer	0.00033	0.00127	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—muscle cancer	0.000317	0.00122	CcSEcCtD
Carfilzomib—PSMB5—Disease—ENO2—muscle cancer	0.000313	0.000889	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ENO2—muscle cancer	0.000313	0.000889	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ENO2—muscle cancer	0.000313	0.000889	CbGpPWpGaD
Carfilzomib—Headache—Doxorubicin—muscle cancer	0.000312	0.0012	CcSEcCtD
Carfilzomib—PSMB8—Disease—ENO2—muscle cancer	0.000309	0.000877	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—CDKN2A—muscle cancer	0.0003	0.000852	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—CDKN2A—muscle cancer	0.000299	0.000848	CbGpPWpGaD
Carfilzomib—Nausea—Doxorubicin—muscle cancer	0.000296	0.00114	CcSEcCtD
Carfilzomib—PSMB10—Cell Cycle—MDM2—muscle cancer	0.000291	0.000827	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—MDM2—muscle cancer	0.00029	0.000823	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—MED12—muscle cancer	0.000288	0.000817	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—MED12—muscle cancer	0.000288	0.000817	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—MED12—muscle cancer	0.000288	0.000817	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HMGA1—muscle cancer	0.000285	0.000808	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HMGA1—muscle cancer	0.000285	0.000808	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HMGA1—muscle cancer	0.000285	0.000808	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—MED12—muscle cancer	0.000284	0.000806	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HMGA1—muscle cancer	0.000281	0.000797	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—FOXO4—muscle cancer	0.000276	0.000785	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—FOXO4—muscle cancer	0.000276	0.000785	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—FOXO4—muscle cancer	0.000276	0.000785	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTCH1—muscle cancer	0.000274	0.000779	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTCH1—muscle cancer	0.000273	0.000775	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—FOXO4—muscle cancer	0.000273	0.000774	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—FOXO1—muscle cancer	0.000269	0.000765	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—FOXO1—muscle cancer	0.000268	0.000762	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—MDM2—muscle cancer	0.000267	0.000757	CbGpPWpGaD
Carfilzomib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000266	0.000756	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—MDM2—muscle cancer	0.000265	0.000754	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ENO2—muscle cancer	0.000262	0.000745	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ENO2—muscle cancer	0.000262	0.000745	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ENO2—muscle cancer	0.000262	0.000745	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ENO2—muscle cancer	0.000258	0.000734	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KIT—muscle cancer	0.000256	0.000729	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KIT—muscle cancer	0.000256	0.000729	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KIT—muscle cancer	0.000256	0.000729	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—FOXO4—muscle cancer	0.000255	0.000725	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—FOXO4—muscle cancer	0.000255	0.000725	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—FOXO4—muscle cancer	0.000255	0.000725	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000254	0.000722	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000254	0.000722	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000254	0.000722	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KIT—muscle cancer	0.000253	0.000718	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—FOXO4—muscle cancer	0.000252	0.000715	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—CDKN2A—muscle cancer	0.000251	0.000712	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—FOXO1—muscle cancer	0.000249	0.000707	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—FOXO1—muscle cancer	0.000248	0.000703	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—FOXO4—muscle cancer	0.000236	0.00067	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—FOXO4—muscle cancer	0.000235	0.000667	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CNR1—muscle cancer	0.000231	0.000658	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	0.000231	0.000655	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CNR1—muscle cancer	0.00023	0.000654	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—CDKN2A—muscle cancer	0.000227	0.000646	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—CDKN2A—muscle cancer	0.000227	0.000646	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—CDKN2A—muscle cancer	0.000227	0.000646	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—CDKN2A—muscle cancer	0.000224	0.000637	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MDM2—muscle cancer	0.00022	0.000626	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MDM2—muscle cancer	0.00022	0.000626	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MDM2—muscle cancer	0.00022	0.000626	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MDM2—muscle cancer	0.000217	0.000618	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTCH1—muscle cancer	0.000208	0.00059	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTCH1—muscle cancer	0.000208	0.00059	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTCH1—muscle cancer	0.000208	0.00059	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KIT—muscle cancer	0.000205	0.000583	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTCH1—muscle cancer	0.000205	0.000582	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KIT—muscle cancer	0.000204	0.00058	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—FOXO1—muscle cancer	0.000204	0.00058	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—FOXO1—muscle cancer	0.000204	0.00058	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—FOXO1—muscle cancer	0.000204	0.00058	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—MDM2—muscle cancer	0.000202	0.000574	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—MDM2—muscle cancer	0.000202	0.000574	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—MDM2—muscle cancer	0.000202	0.000574	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—FOXO1—muscle cancer	0.000201	0.000572	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—MDM2—muscle cancer	0.000199	0.000566	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KIT—muscle cancer	0.000189	0.000538	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IGF2—muscle cancer	0.000189	0.000538	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KIT—muscle cancer	0.000189	0.000536	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—FOXO1—muscle cancer	0.000188	0.000535	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—FOXO1—muscle cancer	0.000188	0.000535	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—FOXO1—muscle cancer	0.000188	0.000535	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IGF2—muscle cancer	0.000188	0.000535	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—FOXO1—muscle cancer	0.000186	0.000528	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FOXO4—muscle cancer	0.000179	0.000508	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FOXO4—muscle cancer	0.000179	0.000508	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FOXO4—muscle cancer	0.000179	0.000508	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FOXO4—muscle cancer	0.000176	0.000501	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CNR1—muscle cancer	0.000175	0.000498	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CNR1—muscle cancer	0.000175	0.000498	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CNR1—muscle cancer	0.000175	0.000498	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—FOXO1—muscle cancer	0.000174	0.000495	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—FOXO1—muscle cancer	0.000173	0.000492	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CNR1—muscle cancer	0.000173	0.000491	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—muscle cancer	0.000167	0.000474	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—muscle cancer	0.000166	0.000472	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MDM2—muscle cancer	0.000162	0.000459	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MDM2—muscle cancer	0.000161	0.000457	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KIT—muscle cancer	0.000156	0.000442	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KIT—muscle cancer	0.000156	0.000442	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KIT—muscle cancer	0.000156	0.000442	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KIT—muscle cancer	0.000153	0.000436	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00015	0.000426	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FH—muscle cancer	0.00015	0.000425	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MDM2—muscle cancer	0.000149	0.000424	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MDM2—muscle cancer	0.000149	0.000422	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000144	0.00041	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PTGS2—muscle cancer	0.000144	0.000409	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KIT—muscle cancer	0.000144	0.000408	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KIT—muscle cancer	0.000144	0.000408	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KIT—muscle cancer	0.000144	0.000408	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF2—muscle cancer	0.000143	0.000407	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF2—muscle cancer	0.000143	0.000407	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF2—muscle cancer	0.000143	0.000407	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PTGS2—muscle cancer	0.000143	0.000407	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KIT—muscle cancer	0.000142	0.000402	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF2—muscle cancer	0.000141	0.000402	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KIT—muscle cancer	0.000133	0.000377	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KIT—muscle cancer	0.000132	0.000375	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FOXO1—muscle cancer	0.000132	0.000375	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FOXO1—muscle cancer	0.000132	0.000375	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FOXO1—muscle cancer	0.000132	0.000375	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FOXO1—muscle cancer	0.00013	0.00037	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—muscle cancer	0.000127	0.000359	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—muscle cancer	0.000127	0.000359	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—muscle cancer	0.000127	0.000359	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—muscle cancer	0.000125	0.000354	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MDM2—muscle cancer	0.000123	0.000348	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MDM2—muscle cancer	0.000123	0.000348	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MDM2—muscle cancer	0.000123	0.000348	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MDM2—muscle cancer	0.000121	0.000343	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTGS2—muscle cancer	0.00012	0.000342	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTGS2—muscle cancer	0.00012	0.000341	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000114	0.000323	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MDM2—muscle cancer	0.000113	0.000321	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MDM2—muscle cancer	0.000113	0.000321	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MDM2—muscle cancer	0.000113	0.000321	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MDM2—muscle cancer	0.000112	0.000317	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—muscle cancer	0.000109	0.00031	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—muscle cancer	0.000109	0.00031	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—muscle cancer	0.000109	0.00031	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—muscle cancer	0.000107	0.000305	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MDM2—muscle cancer	0.000105	0.000297	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MDM2—muscle cancer	0.000104	0.000296	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIT—muscle cancer	0.000101	0.000286	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIT—muscle cancer	0.000101	0.000286	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KIT—muscle cancer	0.000101	0.000286	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KIT—muscle cancer	9.92e-05	0.000282	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—muscle cancer	9.13e-05	0.000259	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—muscle cancer	9.13e-05	0.000259	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—muscle cancer	9.13e-05	0.000259	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—muscle cancer	9e-05	0.000256	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.6e-05	0.000244	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MED12—muscle cancer	8.46e-05	0.00024	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—muscle cancer	7.94e-05	0.000225	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—muscle cancer	7.92e-05	0.000225	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—muscle cancer	7.92e-05	0.000225	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—muscle cancer	7.92e-05	0.000225	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—muscle cancer	7.9e-05	0.000224	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—muscle cancer	7.81e-05	0.000222	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—muscle cancer	7.71e-05	0.000219	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—muscle cancer	6.01e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—muscle cancer	6.01e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—muscle cancer	6.01e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—muscle cancer	6e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—muscle cancer	5.97e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—muscle cancer	5.93e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—muscle cancer	4.54e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—muscle cancer	4.54e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—muscle cancer	4.54e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—muscle cancer	4.48e-05	0.000127	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—muscle cancer	2.69e-05	7.63e-05	CbGpPWpGaD
